Christopher P. Leamon - 05 Jan 2023 Form 4 Insider Report for Fusion Pharmaceuticals Inc.

Role
Chief Scientific Officer
Signature
/s/Maria Stahl as Attorney-in-Fact for Christopher Leamon
Issuer symbol
N/A
Transactions as of
05 Jan 2023
Net transactions value
$0
Form type
4
Filing time
09 Jan 2023, 05:44:50 UTC
Previous filing
02 Nov 2021
Next filing
05 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +250,000 $0.000000 250,000 05 Jan 2023 Common Stock 250,000 $3.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in 48 equal monthly installments beginning on February 5, 2023.